516 patents
Page 11 of 26
Utility
Process and Intermediates for Preparing a JAK1 Inhibitor
24 Feb 22
The present invention is related to processes for preparing itacitinib, or a salt thereof, and related synthetic intermediates related thereto.
Jiacheng Zhou, Shili Chen, Pingli Liu, David J. Meloni, Yongchun Pan, Naijing Su, Michael Xia
Filed: 17 Aug 21
Utility
Process and Intermediates for Preparing a Jak Inhibitor
24 Feb 22
The present invention is related to processes for preparing ruxolitinib, or a salt thereof, and related synthetic intermediates related thereto.
Jiacheng Zhou, Shili Chen, Pingli Liu, David J. Meloni, James M. Parks, Yongchun Pan, Naijing Su, Michael Xia
Filed: 17 Aug 21
Utility
Heteroaryl Amide Compounds As Sting Activators
24 Feb 22
The present application provides heteroaryl amide compounds that activate the STING pathway to produce interferons, which are useful in the treatment of various diseases including infectious diseases and cancer.
Liangxing Wu, Neil Lajkiewicz, Wenqing Yao
Filed: 6 Jan 20
Utility
Cyclopropylamines as LSD1 inhibitors
15 Feb 22
The present invention is directed to cyclopropylamine derivatives which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
Liangxing Wu, Joel R. Courter, Chunhong He, Xiaozhao Wang, Wenqing Yao, Fenglei Zhang
Filed: 9 Jun 20
Utility
Processes for the Preparation of Arginase Inhibitors and Their Synthetic Intermediates
10 Feb 22
Joseph SCLAFANI, Anthony J. Tomaine, Robert J. Wilson, Daniel Carper, Wayne Han, George Shi, Feiquiang Sun, Guobiao Lu, Jack Liang
Filed: 16 Jul 21
Utility
JAK1 Pathway Inhibitors for the Treatment of Cytokine-related Disorders
10 Feb 22
This disclosure relates to JAK1 pathway inhibitors and the use thereof in treating cytokine-related diseases or disorders such as cytokine release syndrome (CRS), hemophagocytic lymphohistiocytosis (HLH), macrophage activation syndrome (MAS), and CAR-T-cell-related encephalopathy syndrome (CRES).
Michael O'Neill Montgomery, Ahmad Naim, Susan Snodgrass
Filed: 19 Jul 21
Utility
Systems, Methods, and Computer Programs, for Analyzing Images of a Portion of a Person to Detect a Severity of a Medical Condition
10 Feb 22
Methods, systems, and computer programs for monitoring skin condition of a person.
Julian Jenkins, Todd Leathers, Ryad Ali
Filed: 5 Aug 21
Utility
Formulations of an AXL/MER inhibitor
8 Feb 22
The present application relates to pharmaceutical formulations and dosage forms of an AXL/MER inhibitor, or a pharmaceutically acceptable salt, solvate, or hydrate thereof, including methods of preparation thereof, which are useful in the treatment of AXL/MER mediated diseases such as cancer.
William L. Rocco, Francis X. Muller
Filed: 28 Jun 19
Utility
Pyrazolopyridine compounds and uses thereof
8 Feb 22
Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds.
Kai Liu, Jun Pan, Alexander Sokolsky, Oleg Vechorkin, Hai Fen Ye, Qinda Ye, Wenqing Yao
Filed: 10 Feb 20
Utility
Salts and Processes of Preparing a PI3K Inhibitor
27 Jan 22
The present application provides processes for preparing (R)-4-(3-((S)-1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)pyrrolidin-2-one, which is useful as an inhibitor phosphoinositide 3-kinase-delta (PI3Kδ), as well as a salt form and intermediates related thereto.
Lei Qiao, Lingkai Weng, Chongsheng Eric Shi, David Meloni, Qiyan Lin, Michael Xia, Vaqar Sharief, William Frietze, Zhongjiang Jia, Yongchun Pan, Pingli Liu, Tai-Yuen Yue, Jiacheng Zhou
Filed: 1 Jul 21
Utility
Thiazolecarboxamides and pyridinecarboxamide compounds useful as Pim kinase inhibitors
25 Jan 22
The present disclosure describes thiazole and pyridine carboxamide derivatives, their compositions and methods of use.
Chu-Biao Xue, Yun-Long Li, Hao Feng, Jun Pan, Anlai Wang, Ke Zhang, Wenqing Yao, Fenglei Zhang, Jincong Zhuo
Filed: 16 Sep 20
Utility
Sustained Release Dosage Forms for a JAK1 Inhibitor
20 Jan 22
This invention relates to sustained release dosage forms comprising {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharmaceutically acceptable salt thereof, and doses and methods related thereto.
Krishnaswamy Yeleswaram, Bhavnish Parikh, Dilip P. Modi, Trupti Sheth
Filed: 28 May 21
Utility
Pyrazolopyrimidine Compounds and Uses Thereof
20 Jan 22
Oleg Vechorkin, Minh Nguyen, Chao Qi, Anlai Wang, Liangxing Wu, Wenqing Yao, Peng Zhao
Filed: 4 Aug 21
Utility
Tertiary alcohols as PI3K-γ inhibitors
18 Jan 22
Brent Douty, Andrew W. Buesking, David M. Burns, Andrew P. Combs, Nikoo Falahatpisheh, Ravi Kumar Jalluri, Daniel Levy, Padmaja Polam, Lixin Shao, Stacey Shepard, Artem Shvartsbart, Richard B. Sparks, Eddy W. Yue
Filed: 26 Jun 20
Utility
Bicyclic Heterocycles As FGFR4 Inhibitors
13 Jan 22
The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR4 enzyme and are useful in the treatment of FGFR4-associated diseases such as cancer.
Liang Lu, Liangxing Wu, Ding-Quan Qian, Wenqing Yao
Filed: 23 Apr 21
Utility
DIHYDROPYRIDO[2,3-D]PYRIMIDINONE Compounds As CDK2 Inhibitors
13 Jan 22
The present application provides dihydropyrido[2,3-d]pyrimidone inhibitors of cyclin-dependent kinase 2 (CDK2), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.
Alexander Sokolsky, Liangxing Wu, Wenqing Yao
Filed: 10 Jun 21
Utility
Topical formulation for a JAK inhibitor
11 Jan 22
This invention relates to pharmaceutical formulations for topical skin application comprising (R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile, or a pharmaceutically acceptable salt thereof, and use in the treatment of skin disorders.
Bhavnish Parikh, Bhavesh Shah, Krishnaswamy Yeleswaram
Filed: 17 Sep 20
Utility
Pyrrole tricyclic compounds as A2A / A2B inhibitors
11 Jan 22
Xiaozhao Wang, Peter Niels Carlsen, Chunhong He, Taisheng Huang
Filed: 8 Apr 19
Utility
Tricyclic Pyridone Compounds As JAK2 V617F Inhibitors
6 Jan 22
The present application provides tricyclic pyridone compounds that modulate the activity of the V617F variant of JAK2, which are useful in the treatment of various diseases, including cancer.
Kai Liu, Onur Atasoylu, Yu Bai, Andrew W. Buesking, Leah C. Konkol, Cheng-Tsung Lai, Song Mei, Jun Pan, Liangxing Wu, Wenqing Yao
Filed: 1 Jul 21
Utility
Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
4 Jan 22
The present invention provides salt forms of (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile that are useful in the modulation of Janus kinase activity and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.
Hui-Yin Li, James D. Rodgers
Filed: 2 Mar 20